Adoption agents.

• Autores: Jessica Wapner
• Localización: Scientific American, ISSN 0036-8733, Vol. 302, Nº. 6, 2010, págs. 19-20
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • The article discusses the U.S. Orphan Drug Act that funds pharmaceutical research for treatment of illnesses that affect 200,000 U.S. residents or less. Despite the favorable financial arrangements that the law establishes for drug companies to develop such drugs, the article says that drug companies have balked at developing drugs that may help limited numbers of people. In support of this notion, the article cites Peter Saltonstall, president of the patient advocacy group National Organization for Rare Diseases. The U.S. Food and Drug Administration's head of the Office of Orphan Products Designation, Tim Coté, also is cited.